His main research concerns Schizophrenia, Psychiatry, Antipsychotic, Olanzapine and Internal medicine. His Schizophrenia research integrates issues from Haloperidol, Psychosis, Prospective cohort study and Nicotine. Joseph Patrick McEvoy interconnects Emotionality, Clinical trial and Clinical psychology in the investigation of issues within Psychiatry.
Joseph Patrick McEvoy has included themes like Risperidone, Anesthesia and Atypical antipsychotic in his Olanzapine study. His Risperidone research is multidisciplinary, incorporating elements of Quetiapine, Schizoaffective disorder and Randomized controlled trial. The concepts of his Quetiapine study are interwoven with issues in Discontinuation and Perphenazine.
His primary areas of investigation include Psychiatry, Schizophrenia, Antipsychotic, Internal medicine and Olanzapine. Joseph Patrick McEvoy usually deals with Psychiatry and limits it to topics linked to Clinical psychology and Cognition, Neuropsychology and Mental health. His biological study spans a wide range of topics, including Haloperidol, Anesthesia and Psychosis.
His Antipsychotic study combines topics in areas such as Tardive dyskinesia, Discontinuation and Pharmacology, Perphenazine. Joseph Patrick McEvoy combines subjects such as Placebo and Endocrinology with his study of Internal medicine. Joseph Patrick McEvoy focuses mostly in the field of Olanzapine, narrowing it down to matters related to Risperidone and, in some cases, Aripiprazole.
Joseph Patrick McEvoy mainly focuses on Psychiatry, Schizophrenia, Internal medicine, Tardive dyskinesia and Antipsychotic. His Schizophrenia research focuses on Clozapine in particular. His work carried out in the field of Internal medicine brings together such families of science as Oncology and Positive and Negative Syndrome Scale.
Akathisia is the focus of his Antipsychotic research. Joseph Patrick McEvoy works mostly in the field of Schizophrenia, limiting it down to concerns involving Antipsychotic Medications and, occasionally, Olanzapine. His studies in Randomized controlled trial integrate themes in fields like Psychological intervention, Young adult, Quetiapine, Ziprasidone and Aerobic exercise.
Joseph Patrick McEvoy mostly deals with Internal medicine, Antipsychotic, Schizophrenia, Psychiatry and Randomized controlled trial. His studies deal with areas such as Schizoaffective disorder, Olanzapine and Discontinuation as well as Antipsychotic. His Olanzapine study combines topics from a wide range of disciplines, such as Quetiapine, Risperidone and Perphenazine.
His Clozapine study in the realm of Schizophrenia interacts with subjects such as Adiponectin. His study in the field of Positive and Negative Syndrome Scale, Major depressive disorder and Bipolar disorder also crosses realms of Patient-reported outcome. As part of one scientific family, Joseph Patrick McEvoy deals mainly with the area of Randomized controlled trial, narrowing it down to issues related to the Clinical trial, and often Relapse prevention, Psychosis, Sexual dysfunction and Acute Psychotic Episode.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman;T. Scott Stroup;Joseph Patrick McEvoy;Joseph Patrick McEvoy;Marvin S. Swartz.
The New England Journal of Medicine (2005)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Joseph Patrick McEvoy;Jonathan M. Meyer;Donald C. Goff;Henry A. Nasrallah.
Schizophrenia Research (2005)
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey.
Archives of General Psychiatry (2007)
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph Patrick McEvoy;Jeffrey A. Lieberman;T. Scott Stroup;Sonia M. Davis.
American Journal of Psychiatry (2006)
Antipsychotic drug effects on brain morphology in first-episode psychosis
Jeffrey A. Lieberman;Jeffrey A. Lieberman;Gary D. Tollefson;Cecil Charles;Robert Zipursky.
Archives of General Psychiatry (2005)
A National Study of Violent Behavior in Persons With Schizophrenia
Jeffrey W. Swanson;Marvin S. Swartz;Richard A. Van Dorn;Eric B. Elbogen.
Archives of General Psychiatry (2006)
Insight in schizophrenia. Its relationship to acute psychopathology.
Joseph P. McEvoy;L. Joy Apperson;Paul S. Appelbaum;Priscilla Ortlip.
Journal of Nervous and Mental Disease (1989)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
Robert M. Bilder;Robert S. Goldman;Jan Volavka;Pal Czobor.
American Journal of Psychiatry (2002)
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development
T. Scott Stroup;Joseph Patrick McEvoy;Marvin S. Swartz;Matthew J. Byerly.
Schizophrenia Bulletin (2003)
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Jean Pierre Lindenmayer;Pal Czobor;Jan Volavka;Leslie Citrome.
American Journal of Psychiatry (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: